SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky Sells 3,459 Shares

SI-BONE, Inc. (NASDAQ:SIBN) SVP Michael A. Pisetsky sold 3,459 shares of the stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $19.66, for a total transaction of $68,003.94. Following the sale, the senior vice president now owns 264,636 shares in the company, valued at $5,202,743.76. The trade was a 1.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

SI-BONE Stock Up 1.3%

SI-BONE stock opened at $19.71 on Wednesday. The company has a debt-to-equity ratio of 0.22, a quick ratio of 7.22 and a current ratio of 8.25. SI-BONE, Inc. has a 52-week low of $11.70 and a 52-week high of $20.05. The firm has a 50 day moving average price of $15.02 and a two-hundred day moving average price of $15.11. The firm has a market cap of $839.94 million, a price-to-earnings ratio of -21.42 and a beta of 0.82.

SI-BONE (NASDAQ:SIBN) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.24) by $0.09. SI-BONE had a negative net margin of 23.82% and a negative return on equity of 22.51%. The firm had revenue of $47.29 million during the quarter, compared to analyst estimates of $45.13 million. Equities analysts predict that SI-BONE, Inc. will post -0.78 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on SIBN. Truist Financial upped their price objective on shares of SI-BONE from $20.00 to $22.00 and gave the stock a “buy” rating in a research report on Tuesday, May 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 price target on shares of SI-BONE in a report on Tuesday, May 6th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $24.00 price target on shares of SI-BONE in a report on Tuesday, May 6th.

Institutional Trading of SI-BONE

Several hedge funds have recently modified their holdings of the stock. Jane Street Group LLC bought a new stake in shares of SI-BONE in the 1st quarter valued at $1,818,000. Goldman Sachs Group Inc. increased its stake in SI-BONE by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock valued at $5,328,000 after purchasing an additional 83,919 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in SI-BONE during the 1st quarter valued at $225,000. Parkman Healthcare Partners LLC increased its stake in SI-BONE by 6.7% during the 1st quarter. Parkman Healthcare Partners LLC now owns 231,109 shares of the company’s stock valued at $3,242,000 after purchasing an additional 14,509 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in SI-BONE by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.